We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+33.56%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.23B
AUM Growth
+$1.6B
Cap. Flow
+$897M
Cap. Flow %
21.18%
Top 10 Hldgs %
21.32%
Holding
1,176
New
232
Increased
605
Reduced
167
Closed
168

Top Buys

Rank Stock Value
1
BEKE icon
KE Holdings
BEKE
+$84.9M
2
LU icon
Lufax Holding
LU
+$59.6M
3
BABA icon
Alibaba
BABA
+$42.6M
4
JD icon
JD.com
JD
+$41.5M
5
GRPN icon
Groupon
GRPN
+$36.4M

Top Sells

Rank Stock Value
1
PTON icon
Peloton Interactive
PTON
+$25.2M
2
JMIA
Jumia Technologies
JMIA
+$21.7M
3
MTCH icon
Match Group
MTCH
+$20.5M
4
FVRR icon
Fiverr
FVRR
+$15.4M
5
SFIX
Stitch Fix
SFIX
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 34.91%
2 Technology 23.48%
3 Communication Services 13.86%
4 Financials 4.63%
5 Real Estate 4.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
926
Prothena Corp
PRTA
$450M
$10K ﹤0.01%
915
+577
+171% +$6.82K
UPST icon
927
Upstart Holdings
UPST
$3.03B
$10K ﹤0.01%
+262
New +$10.8K
XBIT icon
928
XBiotech
XBIT
$69.2M
$10K ﹤0.01%
670
+422
+170% +$7.78K
PAND
929
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$10K ﹤0.01%
+700
New +$9.74K
AKBA icon
930
Akebia Therapeutics
AKBA
$252M
$9K ﹤0.01%
3,320
+2,100
+172% +$6.13K
AVDL
931
DELISTED
Avadel Pharmaceuticals
AVDL
$9K ﹤0.01%
+1,460
New +$9.13K
IDYA icon
932
IDEAYA Biosciences
IDYA
$3.56B
$9K ﹤0.01%
+665
New +$9.01K
KALA icon
933
KALA BIO
KALA
$14.5M
$9K ﹤0.01%
+1
New +$18.8K
PAHC icon
934
Phibro Animal Health
PAHC
$1.39B
$9K ﹤0.01%
+465
New +$8.55K
PBYI icon
935
Puma Biotechnology
PBYI
$454M
$9K ﹤0.01%
915
+577
+171% +$5.84K
SMMT icon
936
Summit Therapeutics
SMMT
$11.1B
$9K ﹤0.01%
+2,035
New +$8.62K
URGN icon
937
UroGen Pharma
URGN
$2.29B
$9K ﹤0.01%
505
+315
+166% +$6.6K
EIGR
938
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$9K ﹤0.01%
25
+17
+213% +$4.88K
GMDA
939
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$9K ﹤0.01%
+1,175
New +$7.95K
CBAY
940
DELISTED
Cymabay Therapeutics
CBAY
$9K ﹤0.01%
1,580
+994
+170% +$7.52K
HARP
941
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9K ﹤0.01%
+60
New +$9.27K
CNCE
942
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9K ﹤0.01%
+740
New +$8.44K
CLVS
943
DELISTED
Clovis Oncology, Inc.
CLVS
$9K ﹤0.01%
+2,025
New +$10.2K
YGYI
944
DELISTED
Youngevity International, Inc Common Stock
YGYI
$9K ﹤0.01%
31,302
-3,330
-10% -$1.9K
BDSI
945
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$9K ﹤0.01%
2,320
+1,462
+170% +$5.63K
ACIU icon
946
AC Immune
ACIU
$240M
$8K ﹤0.01%
1,645
+1,037
+171% +$5.29K
ALT icon
947
Altimmune
ALT
$599M
$8K ﹤0.01%
+760
New +$8.96K
ANIP icon
948
ANI Pharmaceuticals
ANIP
$1.78B
$8K ﹤0.01%
285
+181
+174% +$5.18K
DNTH icon
949
Dianthus Therapeutics
DNTH
$6.09B
$8K ﹤0.01%
69
+43
+165% +$4.88K
SYRE icon
950
Spyre Therapeutics
SYRE
$9.25B
$8K ﹤0.01%
44
+29
+193% +$6.01K
36 37
38
39 40

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Penserra Capital Management held 1,176 positions worth $4.23B, up 61% from $2.63B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Penserra Capital Management deployed $897M of net new capital in Q4 2020, opening 232 new positions and adding to 605 existing holdings. Its largest new stake was KE Holdings: 1,278,021 shares worth $78.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, down from 35% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Peloton Interactive, an estimated $25.2M trimmed.

  • Penserra Capital Management's largest Q4 2020 buy was KE Holdings: 1,278,021 shares worth $78.6M.
  • Penserra Capital Management added most to Alibaba in Q4 2020, an estimated $42.6M increase.
  • Penserra Capital Management's biggest Q4 2020 reduction was Peloton Interactive, cutting an estimated $25.2M.
  • Penserra Capital Management fully exited Palomar in Q4 2020, selling an estimated $6.65M.
  • Penserra Capital Management's ten largest holdings make up 21% of its $4.23B portfolio in Q4 2020.
  • Penserra Capital Management opened 232 new positions and closed 168 in Q4 2020.
  • Penserra Capital Management's portfolio value rose 61% quarter-over-quarter to $4.23B.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.